Form: SC 13G/A

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

November 14, 2024



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G/A
 
 
Under the Securities Exchange Act of 1934
(Amendment No. 01)*
 
GRACE THERAPEUTICS, INC. 

(Name of Issuer)
 
Common Stock

(Title of Class of Securities)
 
00439U104

(CUSIP Number)
 
September 30, 2024

(Date of Event Which Requires Filing of this Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
     ⌧ Rule 13d-1(b)
 
     □ Rule 13d-1(c)
 
     □ Rule 13d-1(d)
 
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 


 
 

 
 
CUSIP No.  00439U104            
 
           
1   NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
  BANK OF AMERICA CORP /DE/
56-0906609
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)   □
  (b)   ⌧
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
   
  0
     
6   SHARED VOTING POWER
   
  494,698
     
7   SOLE DISPOSITIVE POWER
   
  0
     
8   SHARED DISPOSITIVE POWER
   
  494,698
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  494,698
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
 
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  4.9 %
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  HC
 
FOOTNOTES
   
  Per 8K filed by the issuer with the SEC on October 28, 2024, Grace Therapeutics, Inc. filed a certificate of amendment to its Certificate of Incorporation with the Secretary of State of Delaware solely to change the name of the company from Acasti Pharma Inc. to Grace Therapeutics, Inc. The name change became effective on October 28, 2024. In addition, on October 8, 2024, the CUSIP of the issuer changed from 00430K865 to 00439U104. This filing is submitted based on the Reporting Person beneficial ownership on CUSIP 00430K865 as of September 30, 2024.
 
 

 
 
Item 1.

 
(a)
Name of Issuer
 
 
GRACE THERAPEUTICS, INC.

 
(b)
Address of Issuer’s Principal Executive Offices
 
 
103 CARNEGIE CENTER
SUITE 300
PRINCETON, NJ 08540

Item 2.

 
(a)
Name of Person Filing
 
 
BANK OF AMERICA CORP /DE/

 
(b)
Address of Principal Business Office or, if none, Residence
 
 
BANK OF AMERICA CORPORATE CENTER
100 N TRYON ST
CHARLOTTE, NC 28255

 
(c)
Citizenship
 
 
Delaware

 
(d)
Title of Class of Securities
 
 
Common Stock

 
(e)
CUSIP Number
 
 
00439U104

 
Item 3.
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

 
(e)
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 
(f)
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

 
(k)
A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 
 
 

 
 
Item 4.
Ownership.
 
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 
(a)
Amount beneficially owned: 494,698

 
(b)
Percent of class: 4.9 %

 
(c)
Number of shares as to which the person has:

 
(i)
Sole power to vote or to direct the vote: 0

 
(ii)
Shared power to vote or to direct the vote: 494,698

 
(iii)
Sole power to dispose or to direct the disposition of: 0

 
(iv)
Shared power to dispose or to direct the disposition of: 494,698

Item 5.
Ownership of Five Percent or Less of a Class
 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ⌧.
 
Ownership is 4.9%.
 
Item 6.
Ownership of More than Five Percent on Behalf of Another Person.
 
Not Applicable
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
 
This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiary Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
 
Item 8.
Identification and Classification of Members of the Group
 
Not Applicable
 
Item 9.
Notice of Dissolution of Group
 
Not Applicable
 
 
 

 
 
 
Item 10.
Certification
   
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
 
 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
  BANK OF AMERICA CORP /DE/  
       
Date: November 14, 2024
By:
/s/  Andres Ortiz  
    Andres Ortiz  
    Title:  Authorized Signatory  
       
 
Footnotes:
Attention:
Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)